CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Novel Biologics

NOVEL BIOLOGICS

Enabling cutting edge therapies

Biocon’s path-breaking work in novel biologics and novel targets in large molecules has seen significant results in oncology and immunology. The novel biologics portfolio includes both, in-house as well as partnered products.

null

Bicara Therapeutics, a clinical-stage biotechnology company based in Boston, U.S., anchors the development of a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara has access to the thriving innovation ecosystem in the U.S. enabling it to accelerate the development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru is accelerating the development of cutting-edge therapies to improve outcomes for cancer patients.

global innovations

In-house research capabilities

Access to novel IP, therapeutic modalities, in-vivo and in-vitro models

Toxicology studies

Early regulatory filings

Academic collaborations

novel assets

Monoclonal antibodies against novel targets like CD6, and established targets like EGFR

Bispecific fusion antibodies that explore the role of checkpoint inhibitors

Novels Biologics

BUSINESS INTENT

Create Market Leadership in Innovation

PIPELINE

mAbs against targets like CD6, EGFR; bi-specific fusion mAbs

POTENTIAL

To change the treatment paradigm in inflammation and immunology

null

Biocon & Novels

We are the pioneers in developing, manufacturing and launching BIOMAb-EGFR®, India’s first indigenously produced novel monoclonal antibody for the treatment of head and neck cancer; and ALZUMAb®, the world’s first novel anti-CD6 monoclonal antibody in India, for psoriasis.

More >> 

null

Novels In Pipeline

Our novel biologics under clinical development focus on treatments in autoimmune/ inflammation and oncology. These represent a combination of early and advanced stage assets.

More >>

Biocon Finance
FINANCIAL CALENDAR
KEY THERAPEUTIC AREAS
OUR KEY PRIORITIES
Siddharth Mittal
BOARD OF DIRECTORS
PRESS RELEASES
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>